Sermorelin is sold for many goals, and weight loss is one of the most common, so it is worth tracing the argument from the pituitary to the scale and seeing where the measured evidence runs out. The short version is that it runs out early: the chain of reasoning is plausible at its first step and untested at its last.
Where the weight-loss idea comes from
Sermorelin is the first 29 amino acids of growth-hormone-releasing hormone, and it works by prompting the pituitary to release its own growth hormone in pulses. Growth hormone promotes the breakdown of stored fat, so the proposed chain runs from more hormone pulses to more fat burned and, in the end, to lower weight. What sermorelin measurably does to hormone levels is covered in does sermorelin work.
The first link in that chain has good support in obesity specifically. A 1991 study in men used 24-hour blood sampling to reconstruct how much growth hormone each man released, and found that obese men produced about one fourth as much per day as men of normal weight [1]. They had fewer secretory bursts, and the hormone they did release was cleared from the blood faster.
3.2 vs 9.7
growth hormone secretory bursts a day, obese vs normal-weight men
Veldhuis 1991
¼
daily growth hormone production in obese men relative to normal-weight men
Veldhuis 1991
11.7 vs 15.5 min
half-life of the men's own growth hormone, obese vs normal weight
Veldhuis 1991
The authors also found that the shortfall grew in proportion to the degree of obesity. That is a finding about cause and effect running in an unknown direction, however: low growth hormone may help maintain excess fat, or excess fat may suppress growth hormone, and a correlation cannot say which. Restoring the hormone would only help with weight if the first explanation were the main one, and that is the step no sermorelin trial has tested.
What GHRH trials recorded about body weight
The trials that come closest are small studies in healthy older adults, designed to see whether GHRH could reverse age-related changes rather than to cause weight loss. In one, 11 non-obese men aged 64 to 76 with low IGF-1 injected 2 mg of GHRH(1-29) each night for 6 weeks [2]. Nighttime growth hormone release rose, but weight, body mass index, waist-to-hip ratio and DEXA measures of muscle and fat did not change.
A second trial used a close analog of sermorelin rather than sermorelin itself, [Nle27]GHRH(1-29), in 10 women and 9 men aged 55 to 71 [3]. After 4 weeks of nightly placebo, participants injected 10 micrograms per kilogram each night for 16 weeks. Growth hormone and IGF-1 rose, and lean body mass increased in the men only, but the authors report that body weight was unaffected in both sexes.
Neither study enrolled people with obesity, and neither lasted long enough to rule out a slow effect, so they do not show that sermorelin cannot help with weight. They show that nobody has yet measured it doing so. The same trials, read for their muscle and sleep findings, are compared with growth hormone itself in sermorelin vs HGH.
The closest thing to a test: a GHRH analog in obesity
One randomized trial did give a GHRH analog to adults with obesity. Researchers enrolled 60 abdominally obese adults whose growth hormone secretion was reduced, and gave tesamorelin, a stabilized version of the full 44-amino-acid hormone, at 2 mg once daily or placebo for 12 months [4].
−35 cm²
visceral fat area, tesamorelin vs placebo over 12 months (95% CI −58 to −12)
Makimura 2012
−10 cm²
fat under the skin of the abdomen, not significant (P = 0.40)
Makimura 2012
−37 mg/dl
triglycerides, tesamorelin vs placebo (95% CI −67 to −7)
Makimura 2012
The pattern matters more than any single number. The fat that shrank was the visceral fat packed around the organs, while the fat under the skin did not change significantly, and fasting glucose and HbA1c were unchanged [4]. That is a change in where fat sits, which can matter for heart and metabolic risk, rather than a drop on the scale.
The approved tesamorelin label draws the same line in plain words. It is indicated to reduce excess abdominal fat in adults with HIV-associated lipodystrophy, and it states that the drug “is not indicated for weight loss management as it has a weight neutral effect” [5]. More on that molecule, which is not a sermorelin substitute, is in tesamorelin.
What this means if weight is your goal
Taken together, the evidence says sermorelin raises growth hormone, that a stronger relative of it can move fat away from the organs, and that none of this has yet shown up as weight loss in a trial. A prescriber who offers sermorelin for weight is offering it on the mechanism, and it is fair to ask them which outcome they expect to change and how it will be measured.
The medicines with large randomized weight-loss trials behind them are set side by side in peptides for weight loss, and the sellers who prescribe them are ranked on the weight-loss peptide board. If you are considering sermorelin for its own sake, the sermorelin injection board compares who prescribes it. Every option for this goal is gathered on the weight goal page.
If you are weighing a GLP-1 instead, what the trials recorded is in semaglutide side effects.